Dijon - CHU Bocage

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials
• Neuroendocrine tumours1 trial

Phase

• Phase 31 trial

Status

• Recruiting2 trials

Lead sponsor

• Intergroupe Francophone de Cancerologie Thoracique2 trials

Running trials

• Recruiting

  Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

  NCT06937905· Phase 3· Intergroupe Francophone de Cancerologie Thoracique· Source

  Contact: Côme LEPAGE

• Recruiting

  A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

  NCT06053099· Intergroupe Francophone de Cancerologie Thoracique· Source

  Contact: Ayoube ZOUAK

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• Neuroendocrine tumours1 recruiting